Sponsors / ANTX
ANTX

AN2 Therapeutics, Inc

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
1Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803ANTXPhase 2, Phase 3Terminated2024-12-18Actual

Latest recorded trial changes

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803 · AN2 Therapeutics, Inc

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties; measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 3: Percentage of Participants Achieving Clinical Response

+ Updated value

measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 3: Percentage of Participants Achieving Clinical Response

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803 · AN2 Therapeutics, Inc

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 3: Percentage of Participants Achieving Clinical Response

+ Updated value

measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties; measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 3: Percentage of Participants Achieving Clinical Response

Check registry source · The saved outcome text may be shortened. Check the source for full wording.